Treatment of Advanced Refractory Solid Tumors Based on Precise Thymalfasin-regulated PRaG Mode: an Open-label, Prospective, Multicenter Study (PRaG 5.0 Study)
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Immune checkpoint protein inhibitors (Primary) ; Thymalfasin (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms PRaG 5.0 Study
Most Recent Events
- 04 Jun 2024 Results (As of January 31, 2024 n=6) assessing the efficacy of a meticulously thymalfasin-controlled PRaG regimen in advanced solid tumors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Apr 2023 New trial record